indication

Autism Spectrum Disorder

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
2
2 approved · 0 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
53 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 31 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugCompleted
Cariprazine (Vraylar)
US-approved 2015 · Vraylar
Phase 31 trial
OwnerForest Laboratories
Protection2030

Market size

prevalence as a range, not a number